nature.com

47 articles in the TruthFoundry index. Each links out to the original.

• New antibody-based degrader platform targets GPCRs as drug candidates · A new bifunctional antibody-based degrader platform targets GPCRs as potential drug candidates.
• Researchers develop improved bitopic kinase inhibitor PonatiLink-2 for cancer treatment · Stevenson et al. present systematic design for selective bitopic kinase inhibitors including PonatiLink-2.
• Biopharma patent expirations threaten $300B annual revenue by 2030 · McKinsey analysts outline biopharma portfolio risks from upcoming patent expirations
• FDA publishes regulatory lessons from approved AAV gene therapies · FDA analysts review 8 approved AAV gene therapies to guide future submissions.
• Analysis examines trial-to-approval gap for checkpoint inhibitor combinations · Researchers evaluate low approval rates for immune checkpoint inhibitor combination trials.
• FDA Approves Inovio DNA Immunotherapy For Rare HPV Respiratory Disease · Inovio Pharmaceuticals received FDA accelerated approval for Voceryq plasmid DNA immunotherapy.
• Nanotherapy Targets Senescent Cells · Nanotherapy targeting senescent cells shows promise in preclinical models for aging-related diseases.
• Research targets bacterial SOS response to restore antibiotic efficacy · Study proposes inhibiting bacterial SOS pathway to combat antibiotic resistance
• IL-21 mimic synergizes with KRAS inhibitors for pancreatic cancer treatment · Research identifies IL-21 mimic synergy with KRAS inhibitors for resistant pancreatic cancer
• Antagonizing adenosine receptors found to alleviate cardiac fibrosis · New research identifies adenosine receptors as a target for cardiac fibrosis treatment
• Optimized lipid nanoparticles enable delivery of large RNA genome editing cargo · Research highlights improved lipid nanoparticles for large RNA genome editing delivery
• In vivo engineered CAR NK cells address ex vivo manufacturing barriers · Research highlights in vivo CAR NK cell engineering to solve production challenges
• Academic Centres Critical For Advanced Therapy Capacity Gap Solutions · Academic centres lead advanced therapy development but require supporting infrastructure.
• Base editor genome editing progress reviewed over ten years from lab to clinic · Academic bibliography tracks ten years of base editor development from bench to clinic
• Nature.com displays browser compatibility warning for outdated clients · Nature.com notifies visitors of limited CSS support on older browser versions.
• Researchers identify TRI-611 molecular glue targeting ALK cancer drug resistance · Study presents TRI-611, a brain-penetrant molecular glue degrader for resistant ALK lung cancer
• Immune cell engagers reviewed for autoimmune B cell depletion · Academic citations cover B cell depletion therapies for autoimmune diseases.
• Study explores additional benefits of GLP-1 agonist semaglutide in ageing mice · Researchers published a mouse study on extra effects of semaglutide beyond diabetes and obesity.
• AI Drug Discovery Bottleneck: Lack of Protein Binding Data · Researchers say a lack of protein-small molecule binding data hinders AI drug discovery models.
• FDA approves first gene therapy for Sanfilippo syndrome type A · The US FDA has approved Ultragenyx Pharmaceutical's rebisufligene etisparvovec (Fayuvi) for pediatric patients with Sanfilippo syndrome type A.
• FDA Approves 22 Novel Drugs In Q3 2026, Busiest Quarter This Year · US FDA approved 22 novel drugs in Q3 2026, the highest quarterly count in 2026 so far.
• Psilocybin Prevents Chemotherapy-Induced Nerve Damage in Preclinical Models · A study in Science reports psilocybin prevents chemotherapy-induced peripheral neuropathy in preclinical models.
• AstraZeneca COPD biologic tozorakimab succeeds in phase III trials · AstraZeneca's tozorakimab reduced COPD exacerbations across all patient eosinophil levels.
• Academic Citations Outline Soft Drug Design Principles And Applications · Compiled peer-reviewed papers document soft drug design research and clinical development.
• Research Advances Targeting RNA-Binding Proteins in Cancer Therapy · Scientists identify RNA-binding proteins as viable therapeutic targets for cancer treatment using small molecules and antibodies.
• New drug conjugate chemistry avoids target internalization requirement · Researchers present binding-to-release chemistry for drug conjugates tested in tumour models.
• Rare Disease Treatments Shift from Feasibility to Healthcare System Implementation · Experts argue healthcare systems must align to prioritize, fund, and deliver scalable N-of-1 therapies for rare diseases.
• Refining Therapeutic Targeting of Interleukin-6 via Signalling Mode Selectivity · Researchers propose refining IL-6 therapies by targeting specific signalling modes like trans-signalling to reduce side effects.
• Covalent BAX inhibitor confers cytoprotection against excessive cell death · Researchers identify a covalent BAX inhibitor that protects cells from excessive apoptosis in pathologies like myocardial infarction.
• Scientists Target Norovirus RNA Structures to Control Viral Life Cycle · Researchers aim to understand how regulatory RNA structures in norovirus genomes control viral fitness and immune recognition.